MetaCap

MBX Biosciences Inc. (MBX)

NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

49.55-3.86 (-7.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MBX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.03
52-week range
26.14 – 72.64
Day range
49.36 – 54.43
Volume / Avg
581.89K / 532.80K
Beta
—

52-week range

$26.14$72.64

MBX stock today

MBX Biosciences (MBX) closed at $49.55 on Nov 20, down 7.23% (-$3.86), versus the S&P 500's 3.70% decline. Shares are 31.8% below their 52-week high of $72.64, set on Aug 5, 2026 and 89.6% above the 52-week low of $26.14, in the middle of the past year's range. MBX is up 57.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 83.0%.

MBX Biosciences has posted a net loss over the last twelve months (EPS of -$3.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MBX Biosciences

Company profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Steven L. Hoerter
Headquarters
Carmel, IN
Employees
63
IPO year
2024
Website
mbxbio.com

Financial highlights

Full financials

MBX Biosciences reported a net loss of $87.0 million, compared with a loss of $61.9 million a year earlier. Diluted earnings per share came in at -$2.38.

MBX Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-87.00M$-61.92M$-32.56M
EPS (diluted)$-2.38$-5.82$-31.96

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$95.09+91.91%

  • Strong buy 3
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $80.00High $150.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-1.29 vs $-0.80
Surprise
-61.25%

MBX news

All MBX news

MBX Biosciences peers

Health Care sector
MBX peer companies
CompanyPrice% ChgMarket capCompare
IDYAIDEAYA Biosciences Inc.25.56-2.33%$2.47Bvs MBX
XNCRXencor Inc.33.26-2.21%$2.50Bvs MBX
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs MBX
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs MBX
ZLABZai Lab Limited ADR21.03-4.06%$2.63Bvs MBX
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs MBX
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs MBX
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs MBX

Indexes, lists and sector

MBX Biosciences stock FAQ

What is MBX Biosciences's stock price today?

MBX last traded at $49.55 as of Nov 20, 4:00 PM EST, down 7.23% on the day. Prices are delayed at least 15 minutes.

Who is MBX Biosciences's CEO?

Mr. Steven L. Hoerter is the chief executive officer of MBX Biosciences Inc., which has about 63 employees.

What is the MBX 52-week high?

The 52-week high for MBX is $72.64 and the 52-week low is $26.14. The stock is currently 31.8% below its high.

Compare MBX